Far too often, we have heard about the industry's dissatisfaction with CROs, whether it be slow turnaround time, incomplete data analytics, or missed opportunities to advance drug discovery with robust biomarker analytics. Acutis CEO Jibreel Sarij said, "We are reimagining biomarker discovery at the intersection of DNA, RNA, and protein diagnostics and are rewriting the rules to champion our biopharma partners. His extensive experience includes fostering strategic partnerships, implementing customer-focused programs, and growing complex businesses. Tremaine brings over 26 years of experience within the life sciences and CRO industry. In his new role, Tremaine will oversee commercial operations with an emphasis on collaboration and relentless dedication to clients' success. According to the company, this unique approach builds on the expertise gained through its standard-of-care business, Acutis Diagnostics, which has processed over three million patient samples over the past seven years with turnaround times that have been consistently at the top of the industry. Acutis Biosciences combines a multi-omics biomarker profiling approach with data integration to provide pharmaceutical and biotechnology companies with tools needed to help advance clinical discovery. The company also appointed Troy Tremaine as its Chief Commercial Officer. 06.21.23Īcutis Biosciences, a biomarker discovery provider, opened a state-of-the-art 60,000-square-foot facility in Monmouth Junction, NJ. Troy Tremaine brings more than 26 years of experience within the life sciences and CRO industry. Acutis Biosciences Opens New Facility, Names New CCO
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |